$9.67
-0.72-6.93%
At close: -
$9.67
0.000.00%
After Hours: Apr 17, 4:00 PM EDT
Comments
Loading...
UroGen Pharma Analyst Ratings and Price Targets | NASDAQ:URGN | Benzinga
UroGen Pharma Ltd has a consensus price target of $30.77 based on the ratings of 11 analysts. The high is $55 issued by HC Wainwright & Co. on March 11, 2025. The low is $10 issued by Jefferies on February 8, 2023. The 3 most-recent analyst ratings were released by Goldman Sachs, Scotiabank, and D. Boral Capital on April 17, 2025, April 16, 2025, and March 13, 2025, respectively. With an average price target of $21.33 between Goldman Sachs, Scotiabank, and D. Boral Capital, there's an implied 120.61% upside for UroGen Pharma Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Scotiabank
D. Boral Capital
HC Wainwright & Co.
Ladenburg Thalmann
1calculated from analyst ratings
Analyst Ratings for UroGen Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/17/2025 | Buy Now | 65.46% | Goldman Sachs | Paul Choi58% | $22 → $16 | Maintains | Neutral | Get Alert |
| 04/16/2025 | Buy Now | 137.85% | Scotiabank | — | → $23 | Initiates | → Sector Outperform | Get Alert |
| 03/13/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 468.77% | HC Wainwright & Co. | Raghuram Selvaraju42% | $64 → $55 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 02/25/2025 | Buy Now | 561.84% | HC Wainwright & Co. | Raghuram Selvaraju42% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | 220.58% | Ladenburg Thalmann | Aydin Huseynov33% | → $31 | Assumes | → Buy | Get Alert |
| 02/18/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 01/15/2025 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 12/06/2024 | Buy Now | 158.53% | D. Boral Capital | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 158.53% | EF Hutton | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 10/29/2024 | Buy Now | 158.53% | EF Hutton | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 10/21/2024 | Buy Now | 158.53% | EF Hutton | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 158.53% | EF Hutton | Jason Kolbert42% | $25 → $25 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 313.65% | Oppenheimer | Leland Gershell68% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 10/16/2024 | Buy Now | 561.84% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $64 | Maintains | Buy | Get Alert |
| 10/15/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/14/2024 | Buy Now | 158.53% | EF Hutton | Jason Kolbert42% | → $25 | Initiates | → Buy | Get Alert |
| 10/03/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2024 | Buy Now | 313.65% | Guggenheim | Kelsey Goodwin30% | → $40 | Initiates | → Buy | Get Alert |
| 08/15/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/01/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 453.26% | Ladenburg Thalmann | Matthew Kaplan60% | $48 → $53.5 | Maintains | Buy | Get Alert |
| 06/14/2024 | Buy Now | 313.65% | Oppenheimer | Leland Gershell68% | $32 → $40 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 520.48% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $60 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 230.92% | Oppenheimer | Leland Gershell68% | $34 → $32 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 251.6% | Oppenheimer | Leland Gershell68% | $35 → $34 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | 230.92% | Oppenheimer | Leland Gershell68% | $33 → $32 | Maintains | Outperform | Get Alert |
| 10/04/2023 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 458.43% | HC Wainwright & Co. | Raghuram Selvaraju42% | $23 → $54 | Maintains | Buy | Get Alert |
| 07/31/2023 | Buy Now | 86.14% | Goldman Sachs | Paul Choi58% | $11 → $18 | Maintains | Neutral | Get Alert |
| 06/21/2023 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 127.51% | Oppenheimer | Leland Gershell68% | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2023 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $23 | Reiterates | → Buy | Get Alert |
| 04/10/2023 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $23 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $23 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 3.41% | Jefferies | Chris Howerton63% | $35 → $10 | Downgrade | Buy → Hold | Get Alert |
| 12/12/2022 | Buy Now | 137.85% | HC Wainwright & Co. | Raghuram Selvaraju42% | $26 → $23 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | 106.83% | Berenberg | Anita Dushyanth62% | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for UroGen Pharma (URGN) stock?
The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by Goldman Sachs on April 17, 2025. The analyst firm set a price target for $16.00 expecting URGN to rise to within 12 months (a possible 65.46% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for UroGen Pharma (URGN)?
The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by Goldman Sachs, and UroGen Pharma maintained their neutral rating.
When was the last upgrade for UroGen Pharma (URGN)?
There is no last upgrade for UroGen Pharma
When was the last downgrade for UroGen Pharma (URGN)?
The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
Is the Analyst Rating UroGen Pharma (URGN) correct?
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $22.00 to $16.00. The current price UroGen Pharma (URGN) is trading at is $9.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
